View source for I-124 PET Directed Redifferentiation Therapy for Radioiodine Refractory Thyroid Cancer: the I-FIRST Study

{{item
|type_parameter=research
|description_parameter=For patients with advanced thyroid cancer, tumours that no longer trap radioiodine have an extremely poor prognosis and more effective treatments are urgently required. This study will examine whether redifferentiation therapy is able to resensitize tumours to radioiodine treatment and improve patient survival and quality of life.
|aim_parameter={{aim parameter|This study will examine whether redifferentiation therapy is able to resensitize tumours to radioiodine treatment and improve patient survival and quality of life}}{{aim parameter|We will also determine the affordability of bringing this therapy to the clinic}}
|state_parameter=ongoing
|start_date_parameter=2021-01-01
|end_date_parameter=2026-01-01
|location_parameter=Australia
|location_link=No
|URL_parameter=https://www.grants.gov.au/Ga/Show/6c463857-6f42-4bb8-ad2f-3933a356e2b0
|author_parameter={{author parameter
|aut_nam=Portia Dilena
|aut_url=https://scholars.latrobe.edu.au/pdilena
|aut_con=non contact
}}{{author parameter
|aut_nam=Jack Nunn
|aut_ids=0000-0003-0316-3254
|aut_url=https://orcid.org/0000-0003-0316-3254
|aut_tas=Checked report and added URL
|aut_con=non contact
}}
|contributor_parameter={{contributor parameter
|con_typ=individual
|con_nam=Andrew Scott
|con_tas=Lead Chief Investigator
|con_url=https://www.onjcri.org.au/about-us/andrew-scott/
|con_cop=paid
|con_dates=No
}}
|input_parameter={{input parameter
|inp_typ=funding
|inp_inp=2,708,660.70
|inp_currency=AUD
|inp_url=https://www.grants.gov.au/Ga/Show/6c463857-6f42-4bb8-ad2f-3933a356e2b0
}}
}}